Article
Fast Track Status for the Oncolytic Virus Treatment Being Developed by DNAtrix
The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.
DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. (FDA) has granted Fast Track status for its lead product, DNX-2401, a replication competent adenovirus, for patients with recurrent gliobastoma.
"We're very pleased to receive Fast Track status for DNX-2401 and are pleased that the FDA supports our position that there is an urgent need for additional therapies to treat glioblastoma," said Dr. Frank Tufaro, president and chief executive officer of DNAtrix. "Fast Track status reinforces our goal to quickly move forward with the development of DNX-2401. Recurrent glioblastoma is extremely challenging to treat, and clinical results from DNX-2401 to date indicate that the drug may be an important treatment option for the disease."
Press release: http://on.mktw.net/1nNoVCs
Source: MarketWatch
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
